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1. Introduction 
Soybean (Glycine max) is one of the most important agricultural commodities. It contains 
considerable amounts of nutrients (proteins, fatty acids, minerals, vitamins) and constitutes 
a well known source of bioactive phytochemicals with health-promoting effects, including 
oligosaccharides, lectins, trypsin inhibitors, saponins, phytates, phytosterols, and 
isoflavones (IFs). This legume contains the highest amount of IFs, in the range of 0.1-0.4% 
dry weight (Liu, 2006), the main species being daidzin (4’,7-dihydroxyisoflavone), genistin 
(4’,5,7-trihydroxyisoflavone), and glycitin (7,4’-dihydroxy-6-methoxy-isoflavone), the -
glucosides of daidzein, genistein, and glycitein, respectively. These compounds may be 
found in the free or the conjugate forms: glucosides, acetylglucosides, and 
malonylglucosides. In the acetylglucoside form, IFs are named as 6’’-O-acetyldaidzin, 6’’-O-
acetylgenistin, and 6’’-O-acetylglycycitin. In the malonylglucoside form, their respective 
names are 6’’-O-malonyldaidzin, 6’’-O-malonylgenistin, and 6’’-O-malonylglycitin. 
Since IFs are phytoalexins, their concentrations increase in times of plant stress, such as 
reduced moisture, and are influenced by the environmental conditions. The IF levels and 
distribution of isomers in soybeans depend largely on the genotypes of the soybean variety, 
the crop year and environmental factors such as the location and sowing/harvesting periods 
(Eldridge & Kwolek, 1983; Kitamum et al., 1991; Wang & Murphy, 1994a; Aussenac et al., 
1998). Total IF content in soybean has been described in the range of 300 μg/g to greater 
than 3,000 μg/g among the United States Department of Agriculture (USDA) soybean 
germoplasm collection (www.ars-grin.gov/var/apache/cgi-bin/npgs/html). Considerable 
data on the IFs content of foods are available from USDA (1999) and Jackson & Gilani (2002). 
In general, the amounts of IFs range from ca. 1 to 4 mg/g in soybeans and 0.5 to 2.6 mg/g in 
traditional soy foods such as tofu (Wang & Murphy, 1994b).  
A universal definition for the term “Functional Food” has not been established, and various 
countries and groups of countries apply different meanings to the term. However, it is 
accepted that functional foods are aimed to promote health and well being of the 
consumers. While in some countries foods that supply high amounts of nutrients are 
considered as functional, as well as natural unprocessed foods such as fruits and vegetables, 
there is a trend towards the use of the term exclusively for those foods that exert beneficial 
effects beyond their nutrients only. Consequently, the bioactive components should impart 
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health benefits beyond basic nutrition. The beneficial effects of functional foods are 
attributed to the presence of putative bioactive compounds, and their benefits should be 
demonstrated by means of adequate laboratory and clinical trials. The consumers have the 
right to know what bioactive compounds are contained in a functional food, the amounts 
per serving and how it should be consumed, as well as if the compounds are absorbed and 
exert their action via blood distribution into target organs or if they act locally in the 
gastrointestinal tract, among other issues. It is the role of the governmental agencies to 
analyze, accept or reject the proposed health claims, based on the significant scientific 
agreement standard of evidence available (ADA, 2009; ILSI Europe, 2010) 
The bioactive properties of soy IFs have been evaluated by a variety of in vitro, in vivo and 
clinical studies providing the rationale for their use in the formulation of various functional 
foods directed towards the reduction of risk factors of chronic diseases such as cancer, 
cardiovascular diseases, hypertension, osteoporosis, and neurodegenerative diseases. A 
series of concentrated and purified soybean products are found in the market, including 
pure forms of the putative health-promoting IFs. However, the results of the studies 
designed to demonstrate the beneficial effects of soy IFs represent a challenge due to a series 
of complications that may lead to unresolved issues. The aim of this chapter is to describe 
some of the considerations that should be taken into account when analyzing the 
formulation of novel functional foods containing soy IFs in order to be able to sustain their 
beneficial effects and accept health claims to communicate them to the consumer. 
2. Bioavailability of soy IFs 
2.1 Absorption of soy IFs 
The absorption of IFs differs among populations due to factors such as the composition of 
the intestinal microflora (Xu et al., 1995), dietary habits, and ethnic background (Zubik & 
Meydani, 2003). The first phase of IF absorption, up to one hour, is impaired in lactose 
malabsorbers, which suggests a role for lactase, but overall this is compensated by microbial 
hydrolysis, and Tamura et al. (2008) observed that total absorption was not significantly 
affected by lactose malabsorption. The bioavailability of IFs is further influenced by their 
chemical form in foods, their hydrophobicity and susceptibility to degradation, and the food 
matrix (Birt et al., 2001). Izumi et al. (2000) and Kano et al. (2006) found a greater 
bioavailability of daidzein and genistein, but not their glucosides, whereas Setchell et al 
(2001) reported a more efficient use of glucosides. Other studies reported that the absorption 
of aglycones and glucosides was similar (Tsunoda et al., 2002; Richelle et al., 2002; Zubik & 
Meydani, 2003). It seems that IF aglycones are absorbed faster than glucosides, due to their 
greater hydrophobicity and a smaller molecular weight, whereas glucosides have lower 
absorbability and must be converted to aglycones. 
The absorption of IFs is highly dependent on their chemical form, and the -glucosides 
require hydrolysis to aglycones to be absorbed by the gut and exert their potentially 
protective effects (Setchell et al., 2002a; Zheng et al., 2003). In fact, free IFs reach peak plasma 
levels before the corresponding glycosylated forms (Setchell et al., 2001). Hydrolysis occurs 
along the entire length of the intestinal tract by the action of both the brush border 
membrane and the bacterial -glucosidases and -glucuronidases (Day et al., 1998; Manach 
et al., 2004), while -glucuronidases and sulphatases participate in the reabsorption process 
of the hepatic conjugates and biliary excretion (Xu et al., 2000). The aglycones and bacterial 
metabolites are absorbed from the intestinal tract to undergo enterohepatic recycling 
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(Sfakianos et al., 1997). IFs undergo extensive biotransformation catalyzed by hepatic 
cytochrome P450 (Kulling et al., 2001), producing metabolites that exert antioxidant activity 
(Rüfer & Kulling, 2006). 
The colonic microflora plays important roles in the metabolism of IFs. Daidzein may be 
metabolized to form two IFs: equol (7-hydroxy-3-(4’-hydroxyphenyl)-chroman) and O-
desmethylangolensin (Xiao, 2008). Only near 30% soy consumers produce equol (Lampe et 
al., 1998; Setchell et al., 2002b). The ability to produce equol may be determinant of the 
beneficial effects of IFs, since subjects that are able to form this metabolite exhibit enhanced 
responses to diets containing IFs (Duncan et al., 2000; Setchell et al., 2003a; Akaza et al., 
2004; Vafeiadou et al., 2006).  
De Pascual et al. (2006) determined the effect of food matrix on the levels of IFs attained in 
serum and urine in healthy postmenopausal women given an oral dose of three different 
foods containing 50 mg IFs on three separate occasions. They observed a lower total urinary 
recovery of genistein following ingestion of juice (61%) in comparison with solid foods (66% 
and 70% for bars and cookies, respectively). The levels of daidzein were not altered by food 
matrix and none of the volunteers appeared capable of converting this precursor to equol. 
Serum peak genistein concentrations were attained earlier following consumption of liquid 
matrix, although the differences were not statistically significant. When the authors 
compared the IF concentrations after the technological processing of the different test foods, 
they only found differences in aglycone levels. 
Bacterial species of bacteroides, bifidobacteria and lactobacilli have the highest -
glucosidase activity (Xu et al., 1995). Furthermore, an increase of the intestinal -glucosidase 
activity with the chronic ingestion of soy has been observed (Wiseman et al., 2004). Nielsen 
& Williamson (2007) summarized data from 16 studies on factors affecting the 
bioavailability of IFs, reporting that it increases with a rapid gut transit time and low fecal 
digestion rates and decreases with dietary fiber. Dietary prebiotics (such as 
fructooligosaccharides, FOS) increase the intestinal bioavailability and affect the metabolism 
of IFs in rats (Uehara et al., 2001), and increase microbial production of equol in mice (Ohta 
et al., 2002).  However, Sung & Choi (2008) assayed different doses of IFs in rats (up to 500 
mg/kg diet) and observed that an increased plasma equol level did not offer additional 
protection to that provided by FOS against colon carcinogenesis. These results indicate that 
equol production is not directly related to a health promoting effect, since an inhibitory 
effect on colon cancer in a favorable gut ecosystem was not observed. Moreover, Larkin et 
al. (2007) observed that the addition of neither probiotic bacteria nor resistant starch 
(prebiotic) to a soy diet significantly affect IFs absorption or metabolism. The authors 
propose that since the probiotics L. acidophilus and B.bifidus do not increase -glucuronidase 
activity in the human gastrointestinal tract, the lack of effects observed in the study may 
indicate that -glucuronidase activity is more important than -glucosidase activity in IFs 
bioavailability. 
An important factor affecting the efficiency of cellular uptake by passive diffusion is the 
affinity of the IF molecules to the cellular membrane. Increased order of affinity to liposomal 
membranes have been reported as genistin = daidzin < daidzein < genistein < flavonoid 
aglycones (Murota et al., 2002). 
2.2 Bioavailability of IFs 
One of the requisites a functional food must comply is the demonstration of the 
bioavailability of the putatively active compounds it contains in order to allow their 
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adequate distribution in body tissues and target cells in physiological concentrations. This is 
currently assessed by measuring the bioactives in blood (plasma) and/or their urinary 
excretion. In fact, the rate of excretion of a compound in urine is usually directly 
proportional to the systemically bioavailable fraction. In general terms, although the oral 
bioavailabilities of flavonoids are low (Hu, 2007), the concentrations of their phase II 
metabolites, in particular glucuronides in the body are still appreciable and some of these 
metabolites are also demonstrated to be bioactive (Zhang et al., 2007).  
IF levels in urine and plasma have been widely used as biomarkers of IF intake (Yamamoto 
et al., 2001; Nagata et al., 2006). Franke et al. (2009) reported a good correlation between 
peak concentrations of plasma daidzein and genistein and their concentrations in the first 24 
h urine following soy consumption. Elimination of IFs is predominantly via the urine 
(mainly equol), although total recovery by mass balance is less than 50%, suggesting that 
unrecognized metabolites are being formed. In populations that consume small to moderate 
amounts of soy only occasionally, adherence should be assessed because urinary IFs reflect 
primarily the intake within the past 48 h. Turner et al. (2003) emphasize the role of the gut 
microflora on the bioavailability of IFs by stating that studies involving the metabolism of 
functional food components should focus on the bacteria inhabiting the small intestine, 
where absorption takes place, in order to facilitate the manipulation of factors influencing 
their activity and hence bioavailability of IFs. 
Setchell et al. (2003a) observed that IFs are absorbed relatively quickly, attaining maximum 
serum concentrations from 2 to 8 h after ingestion, with means for daidzein and genistein of 
6.1 and 5.0 h, respectively. The bioavailability, obtained from the area under the curve 
(AUC) of plasma concentration vs. time, showed a curvilinear relationship with increasing 
levels of IFs ingested, especially in the dose range of 0.4–1.8 mg/kg body weight. The 
authors attribute the reduced systemic availability to reduced absorption of IFs with 
increasing levels of intake. The pharmacokinetics and systemic bioavailability of -
glycosides has been found to be greater than the corresponding aglycones in dose-
normalized AUCs, and relatively small proportions of aglycones appear in plasma even 
after an ingestion of high amounts of these compounds (Setchell et al., 2001). The actual 
composition of most IF–rich ingredients to be used in functional foods and dietary 
supplements are not completely known, and it would be very advantageous to direct the 
chemical composition of the formulation towards the expected clinical effect expected. A 
review of the analytical methods available for the analysis of IFs in foods, supplements and 
biological samples was recently published by Hsu et al. (2010). 
Zhou et al. (2008) demonstrated that the absorption, biotransformation, and excretion of 
genistein show a nonlinear dose-dependent relationship at high doses in rats. They 
observed that genistein (free and glucuronidated) can be detected in plasma within 5 min 
after oral administration, indicating that this compound can be quickly absorbed and 
metabolized in the gastrointestinal tract. The authors reported that the primary form of 
genistein in plasma is the glucuronidated form due to the action of the gut microflora 
(Sfakianos et al., 1997). In effect, the majority of metabolite is genistein-7-O--D-glucuronide; 
other metabolites include genistein-4′-O-sulfate and genistein-4′-O-sulfate-7-O--D-
glucuronide, which are formed in smaller amounts (Yasuda et al., 1996; Prasain et al., 2006). 
Since glucuronidated genistein can be further deconjugated by glucuronidase in the 
intestine, the released genistein can be absorbed, metabolized, and excreted for a second 
time (enteric recycling and enterohepatic circulation). Thus, the exposure time of the body to 
genistein is prolonged. However, its bioavailability is low, due to its poor absorption and its 
significant first-pass metabolism (glucuronidation and sulfation) (Chen et al., 2005). 
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Urinary IFs are frequently used as biomarkers of their potential bioavailability from foods or 
supplements rich in these compounds (Faughnan et al., 2004). Urine is easy to collect and 
contains 100-fold higher concentrations of IFs as the plasma levels (Setchell et al. 2001, 
2003b). It is usually collected for 24 h and correlates well with serum assessment of systemic 
bioavailability of IFs (Setchell et al. 2003a). Additionally, quantitative assessment in urine 
provides information on the extent of intestinal metabolism of IFs and subject compliance in 
intervention trials.  
Daidzein and genistein are the two main IFs excreted in the urine after soy foods are 
consumed, and daidzein is always excreted in greater amounts than genistein in the urine of 
adults (Kirkman et al., 1995). However, only a small proportion of dietary IFs are excreted in 
urine (1–25%). Therefore, they may be not absorbed from the gut, absorbed and released in 
bile followed by faecal excretion, or metabolized by gut microflora or the liver (Scalbert & 
Williamson, 2000).  
On the other hand, Lampe et al. (1999) observed higher urinary lignan and phytoestrogen 
excretion in individuals consuming higher amounts of fruits and vegetables as well as sex 
differences in IF excretion, since men exhibit higher urinary excretion of genistein and 
daidzein. In fact, the urinary recovery appears to be influenced by gender and the food 
matrix (Lu & Anderson, 1998), with longer half-lives for daidzein and genistein in females 
compared with males. Moreover, the production of equol differs among postmenopausal 
women populations, and Chanteranne et al. (2008) classified the population of different 
countries in three groups, according to the magnitude of equol production, as high, medium 
and very low. The authors observed that French volunteers were the main equol producers 
(42%), in opposite to Italy (30%) or the Netherlands (21%). In each country, daidzein 
concentrations in plasma were lower than those of genistein, which reflect the ingested 
proportions, and the reverse was observed in urine. 
As stated by Martin et al. (2008), collectively current data suggest that the bioavailability of 
soy IFs is in the range of 20-30% in both animals and humans, reaching plasma 
concentrations in the range of high nanomolar to low micromolar in both animals and 
humans. 
2.3 Types of studies 
In order to substantiate health protective functions claims, appropriate human-intervention 
trials and other clinical studies must be made. Intervention studies are quite complex, since 
they demand the participants to restrain completely from certain foods or drinks and to be 
randomly assigned to consume a test product or placebo even for several years, among 
other requisites. To overcome the need for long-term intervention studies, alternatives 
include the use of validated biomarkers to predict certain disease risk factors, which 
represents a challenge. In the latter years, metabolomic techniques that help to identify the 
response of each individual to the dietary intake of bioactives constitute a promising 
method for studying mechanisms of action (Gibney et al., 2005; Fardet et al., 2008). 
Many conflicting results have been obtained stating the relationship between soy IFs and 
health-related endpoints. This is often associated to a reductionist approach to the study, 
assuming that the effects of feeding a soy food reflect the activity of one or a few related soy 
components; that the activity of a purified soy component reflects the effects of eating whole 
soy foods; or that soy foods equal IFs that are either estrogenic or antiestrogenic, which 
explains the biological effects observed. Animal studies demonstrate that these assumptions 
are false (Naciff et al., 2005; Badger et al., 2008; Chen et al., 2008; 2009; Singhal et al., 2009). 
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Bioavailability and potential modes of action of various soy constituents differ, and most 
ingredients act via multiple mechanisms (van Ee, 2009). In addition, soy constituents may 
potentially interact synergistically in maintaining/obtaining study endpoints. 
In vitro assays are usually performed to explore bioactivity. The main flaw of these studies is 
due to the use of supraphysiological levels of isolated IFs or mixtures of IFs in cell cultures, 
over- or underestimating in vivo effects (Stevenson & Hurst, 2007). Therefore, the relevance 
of these assays to human situations is uncertain and the results should be interpreted with 
caution, although they may be helpful in determining the mechanisms by which soy IFs 
may exert their effects at cellular and molecular levels (Erdman et al., 2004). On the other 
hand, animal models are not completely comparable to humans. IF metabolism in rodents 
and nonhuman primates differ markedly from that of humans (Gu et al., 2006). Moreover, 
animals may be fed with very high amounts of soy, at levels exceeding what can be 
administered in clinical trials. If the IFs are administered to animals by injection, they would 
bypass the gastrointestinal tract and liver and may also exceed the exposure of human 
consumption.  
The bioavailability of IFs depends upon factors such as solubility, partition coefficient, 
permeability, metabolism, excretion, target tissue uptake, and disposition of the bioactives 
(Karakaya, 2004), all of which make the results of the studies controversial. It is critical that 
IF blood levels (total and aglycone) be evaluated and be comparable to the blood levels 
observed in human populations consuming IF-containing products. Besides, the intestinal 
microflora of animals may be more efficient at producing equol and consequently, results of 
studies in these species may not predict the effect of soy consumption in humans.  
In the US, the National Institutes of Health (NIH) launched the Justification for Clinical 
Research Guidance (http://grants.nih.gov), while the Food and Drug Administration (FDA) 
published the Clinical Trials Guidance Documents (http //www.fda.gov/RegulatoryInforma 
tion/Guidances/ucm122046.htm), which establish the variables to be taken into consideration 
in cell culture, animal and clinical studies as well as product characterization, stability, and 
analytical methods used to determine product integrity, among others. For instance, although 
epidemiological studies of Asian populations provide the background for many clinical 
studies, the type of soy Asians consume often differs from that consumed by other 
populations. Also, few dose-response trials have been conducted in humans, so it is difficult to 
estimate with confidence the threshold amount of soy needed to exert various physiologic 
effects in vivo.  
The NIH commissioned the National Center for Complementary and Alternative Medicine 
and the Office of Dietary Supplements to review the evidence-based scientific reports on the 
effects of soy intake, through the Agency for Health Care Research and Quality (AHRQ) 
(Balk et al., 2005). The document, titled “Effects of Soy on Health Outcomes,” summarized 
the formulations of soy products and/or soy food used in clinical trials and the current 
evidence of the health effects of soy and its constituents on cardiovascular disease, 
menopausal symptoms, endocrine function, cancer, bone health, reproductive health, 
kidney function, cognitive function, and glucose metabolism. Specifically, the NIH launched 
the Soy Research Guidelines, a document that addresses the following items to be 
considered in a study: 1) The need for sound justification for studying the health effects of 
soy in humans; 2) Approaches to understanding and ensuring product composition and 
integrity; 3) Methods for assessing exposure to non-study soy and intervention adherence; 
4) Some appropriate analytical methods to test the products; 5) The importance of 
understanding how soy is processed and how it acts in the body: and 6) The role that genetic 
makeup may play in the health effects of soy (Klein et al., 2010).  
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An important source of conflicting results is the use of diverse forms of soy products. The 
soybean contains 12 forms of IF isomers, including the 3 aglycones, their respective -
glycosides, and 3 -glucosides, each esterified with either malonic or acetic acid. The type 
and concentrations of these isomers in foods will vary depending on the plant part from 
which they are derived and the method by which they are processed (Coward et al., 1993; 
Erdman et al., 2004; Choi & Rhee, 2006). For instance, some soy products are designed to be 
very bland and are made from soy flour that has been treated with hot aqueous ethanol. 
Since this solvent extracts the IFs, these products are essentially IF-free (Barnes, 2008). Total 
IF content has been reported in the range of 60 to 340 mg/100 g for soy ingredients such as 
defatted and whole soy flours (90-95% glycosylated), soy protein isolates (20-55% aglycones) 
and textured soy proteins (90-95% glycosylated, but 15-25% acetylglycosides) (Genovese & 
Lajolo, 2010).  
Since the IF content of foods is often reported without indicating whether it refers to 
aglycone or glycoside, Klein et al. (2010) propose the use of the term “aglycone IF 
equivalents” to describe the bioactive form of IFs, since cleavage of the glycosides is 
probably required before the compounds can be absorbed. As a result, IF values could be 
converted to aglycone equivalents if desired.  
3. Health claims 
3.1 Cardiovascular health 
The beneficial effects of fruits and vegetables have been largely ascribed to polyphenols, 
since these bioactives affect dyslipidemia and atherosclerosis; endothelial dysfunction and 
hypertension; platelet activation and thrombosis; the inflammatory process associated with 
the induction and perpetuation of cardiovascular diseases (Fraga et al., 2010). 
In spite of the great amount of scientific reports demonstrating the beneficial effects of IFs in 
a variety of assays in vitro, in vivo and clinical studies, as well as their mechanisms of action, 
the only health claim currently approved by the US FDA relates the intake of soy protein to 
the protection of cardiovascular health, establishing that an amount of 25 g of soy protein 
should be consumed on a regular daily basis (FDA, 1999).  The exact mechanism by which 
soy lowers blood lipids remains unclear, but in 1999 the FDA approved the health claim 
stating that the inclusion of soy protein into a diet low in saturated fat and cholesterol may 
reduce the risk of coronary heart disease by lowering blood cholesterol levels. Due to the 
inconsistency of the results of the studies available, the National Center for Complementary 
and Alternative Medicine and the Office of Dietary Supplements, both of NIH, reviewed the 
evidence-based literature and published a report through the Agency for Health Care 
Research and Quality (AHRQ) (Balk et al., 2005).  
The European Food Safety Authority analyzed the claimed effect for soy protein stating that 
“reduces blood cholesterol and may therefore reduce the risk of (coronary) heart disease” 
(EFSA, 2006). Clinical studies were provided to sustain the claim, most of which were 
randomized controlled trials. Meta-analyses and a review of possible mechanisms by which 
soy protein might exert the claimed effect were all examined. However, most of these 
studies were not appropriately designed to test the effect of soy protein per se, but were 
conducted using either soy protein isolate (SPI, by definition contains 90% protein) or soy 
foods containing other constituents that may exert an effect on blood cholesterol in human 
intervention studies (e.g., fat and fatty acids, fiber, IFs). The Panel considered that the design 
of the studies on SPI did not address the effects of the food constituent that is the subject of 
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the health claim on LDL-cholesterol concentrations. Then new intervention studies were 
included in a new meta-analysis which aimed to address the effects of soy protein per se on 
blood cholesterol concentrations, and there was a statistically significant dose-response 
relationship between the intake of IFs and the decrease in total and LDL-cholesterol 
concentrations. One study was designed to assess the effects of IF-containing and of IF-free 
SPI on biomarkers of cardiovascular risk, including blood lipids. No significant differences 
were observed between the SPI with no IFs (or the SPI with IFs) and the control group with 
respect to changes in total or LDL-cholesterol concentrations during the study. The EFSA 
Panel concluded that this study did not support an effect of the protein component of soy on 
LDL-cholesterol concentrations.  
In weighing the evidence, the EFSA Panel took into account that the results from human 
intervention studies identified as being controlled for the macronutrient composition of the 
test products did not support an effect of the protein component of soy on LDL-cholesterol 
concentrations, and that the proposed mechanism by which the protein component of soy 
would exert the claimed effect is not supported by available scientific evidence. 
Consequently, a cause and effect relationship was not established between the consumption 
of soy protein and the reduction of LDL-cholesterol concentrations (Scientific Opinion on 
the substantiation of a health claim related to soy protein and reduction of blood cholesterol 
concentrations pursuant to Article 14 of the Regulation (EC) No 1924/2006, published: 30 
July 2010).  
The “Dietary Approaches to Stop Hypertension” (DASH) study (Sacks et al., 2001) showed 
that blood pressure levels may be lowered with a healthy eating plan that includes fruits 
and vegetables, is low in total fat, saturated fat, and cholesterol. Antihypertensive effects of 
soy IFs have been reported for over a decade, although the results of the clinical studies and 
the ability of specific dietary compounds to lower blood pressure is still controversial. 
Nestel et al. (1997) observed that IFs improve systemic arterial compliance. A 
cardioprotective effect of genistein was observed in association with its ability to lower 
blood pressure in postmenopausal women (Teede et al., 2001). However, the same authors 
(Teede et al., 2006) did not report any beneficial effects on arterial function after three 
months of soy protein dietary supplementation containing IFs in hypertensive men and 
postmenopausal women.  
A number of the cardiovascular protective actions of IFs have been associated to their effects 
on thromboxane A2 (TxA2), a pro-atherogenic metabolite of arachidonic acid, since the 
stimulation of TxA2 receptors activates a series of cell signals involved in the development 
of atherogenesis (Huang et al., 2004). Genistein inhibits TxA2-mediated platelet responses 
(Nakashima et al., 1991), acting as an antagonist of TxA2 receptors, and the same action has 
been described for equol (Munoz et al., 2009). These molecules compete with TxA2 receptors 
and decrease their density (Garrido et al., 2006). Genistein and daidzein inhibit platelet 
adhesion and aggregation (Sargeant et al., 1993; Gottstein et al., 2003; Borgwardt et al., 2008) 
and inhibit the secretory activity of platelets (Guerrero et al., 2005; Munoz et al., 2009).  
IFs also exert anti-inflammatory effects, and Huang et al. (2005) observed a 66.7% reduction 
of TNF- in postmenopausic healthy women who consumed soymilk containing 112.2 mg 
IFs for 16 weeks, while Chan et al. (2008) observed a reduction of C-reactive protein with IFs 
supplement in patients with ischaemic stroke, improving their endothelial function. Soy IFs 
have been shown to inhibit TNF- induced NF-B activation (a transcription factor that 
regulates genes involved in inflammation, cytokine response, and cell proliferation and 
survival) in cultured human lymphocytes, growth control and its supplementation in 
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healthy men was shown to prevent NF-B activation by TNF- in blood lymphocytes (Davis 
et al., 2001). Choi et al. (2011) demonstrated that soybean and two Korean traditional 
fermented soybean products modulate inflammation-related NF-B activation in Sprague–
Dawley rats fed a high-fat diet. The authors report that the expressions of NF-B related 
proinflammatory genes, notably COX-2, iNOS, and that of the adhesion molecule VCAM-1, 
increased with the feeding of a high-fat diet, but that soybean and fermented soybean 
products modulated these gene expressions.  
Besides, several studies have shown that endothelial nitric oxide synthase (eNOS) 
expression is increased following treatment with dietary soy (Mahn et al., 2005) or genistein 
(Squadrito et al., 2003; Si et al., 2008), increasing nitric oxide (NO) production, thus 
improving vascular function. Joy et al. (2006) showed that rapid activation of eNOS with IFs 
includes interaction between multiple signaling pathways, involving activation of the 
ERK1/2 pathway, and activation of the PI3 kinase/Akt pathway (Tissier et al., 2007), 
resulting in phosphorylation of eNOS and subsequent association of eNOS with heat shock 
protein 90, which participates in the activation of this enzyme. Mann et al. (2007) reported 
that an important aspect of the vascular response to IFs involves increased expression of 
components of cellular antioxidant mechanisms, since IFs may amplify NO signaling 
increasing NO bioavailability by directly quenching reactive oxygen species. Moreover, IFs 
also reverse vascular contraction through inhibitory interactions with a number of vascular 
constriction mechanisms (Joy et al., 2006). 
Other actions of soy IFs have been reported that may aid in the cardiovascular protection, 
such as a decrease of body fat in older ovariectomized mice (Naaz et al., 2003), and rats (Kim 
et al., 2006), an inhibitory effect on the enlargement of adipose tissue (Ørgaard & Jensen, 
2008), and the reduction of fasting blood glucose and lipid levels (Park et al., 2006), 
contributing to prevent obesity-associated diseases. However, care should be taken when 
describing these actions, since many of the studies have been performed in vitro or animal 
studies using concentrations that are unexpected to be reached from a dietary intake of IFs.  
3.2 Bone health and menopausal symptoms 
IFs possess estrogenic activity in animals at concentrations lower than 0.1 μM based on the 
direct interactions between IFs and estrogen receptors (ERs): ER and ER, providing these 
polyphenols the ability to act as estrogen agonists or antagonists (Messina, 2010a). This 
chapter does not describe the effects of soy IFs on circulating levels of estrogens and other 
hormones in women, and the extensive review and meta-analysis of the literature to 
examine these effects published by Hooper et al. (2009) is recommended. Since a variety of 
functional foods especially formulated for women are marketed considering the putative 
beneficial effects of IF intake on bone health and menopausal symptoms, these subjects are 
briefly described.   
Epidemiological Asian studies have found that postmenopausal women with the highest 
intake of IF-rich soy foods have the highest bone mineral density (BMD) in the lumbar spine 
compared with women with low intakes (Somekawa et al., 2001; Mei et al., 2001). The 
evidence of a bone health protective effect of IFs is associated to their ability to bind 
selectively to estrogen receptors (Kuiper et al., 1997). These compounds stimulate 
osteoblasts and inhibit osteoclast activity in vitro, effects that are consistent with reduced 
bone turnover (Rassi et al., 2002; Chen et al., 2003). Besides, animal studies have shown 
bone-sparing effects of soy protein or IFs (Setchell & Lydeking-Olsen, 2003), while short-
term human studies have demonstrated that IFs can reduce bone loss in postmenopausal 
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women (Potter et al., 1998; Scheiber et al., 2001). In a model of ovariectomized rats, Al-
Nakkash et al. (2010) after 2 weeks of genistein treatment (250 mg/kg body weight) 
observed increased uterine weight, femur weight, and femur-to-body weight ratio, estrogen-
like effects that were not associated to oxidative stress. According to Lydeking-Olsen et al. 
(2004), soy foods with IFs can prevent bone loss of the lumbar spine in postmenopausal 
women, who may otherwise lose 1.5–3% of bone/year. This prevention of bone loss, if 
continued into old age, could translate into a decrease in lifetime risk of osteoporosis and a 
lowering of fracture rates. 
The North American Menopause Society (2000; 2006) stated that “the role of IFs in the 
management of short-term menopausal symptoms as well as diseases related to 
menopause/aging is still uncertain…” These reports, however, were retired. In a review on 
the subject of the anti/proestrogenic effects of IFs in breast cancer, Hasler & Kundrat (2002) 
emphasize that clinical trials are needed in order to clearly establish the potential beneficial 
effects. Although a series of subsequent papers report beneficial effects of the intake of soy 
IFs on BMD (Atkinson et al., 2004; Kreijkamp-Kaspers et al., 2004), the situation remains 
unclear. Tests have been performed using pharmaceutical forms also, and Marini et al. 
(2007) administered 54 mg/day tablets of purified genistein to postmenopausal women, 
evidencing a significant increase in BMD in certain locations vs. placebo.  
More recently, the North American Menopause Society (2010) stated that the evidence of the 
benefits of the consumption of IFs on bone health is weak, regardless of the food source. In 
agreement with this statement, the EFSA analyzed the claimed effect of IFs on bone health, 
related to bone mass, BMD, and bone structure, all of which contribute to bone strength. 
However, although significant effects on markers of bone turnover and/or on spine BMD 
have been described in some short-term randomized trials in relation to the dietary intake of 
soy IFs, longer-term interventions do not support a sustained effect of soy IF intake on 
markers of bone health. The Panel also took into account the lack of a clear dose-response 
relationship between the dietary intake of soy IFs and the claimed effect, and the different 
results obtained depending on the source and nature of the IFs used. In conclusion, it stated 
that the evidence provided was not sufficient to establish a cause and effect relationship 
between the consumption of soy IFs and the maintenance of BMD in post-menopausal 
women (EFSA Scientific Opinion on the substantiation of health claims related to soy IFs 
and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation 
(EC) No 1924/2006, published: 1 October 2009).  
3.3 Antioxidant effects 
The antioxidant capacity of IFs has been observed mostly in vitro (Ruiz-Larrea et al., 1997; 
Rüfer & Kulling, 2006). However, as it has been described to polyphenols in general, IFs 
may act as indirect antioxidants by up-regulating endogenous antioxidant enzymes 
(Stevenson & Hurst, 2007; Kampkotter et al., 2008). Borras et al. (2006) observed that 
genistein at low micromolar physiological levels up-regulates the expression of longevity-
related genes in a manner similar to 17 -estradiol, involving interactions with estrogen 
receptors, activation of ERK1/2 and NFB and up-regulation of longevity-related gene 
expression. In vivo, Wiseman et al. (2000) observed that dietary soy IFs decrease F(2)-
isoprostane concentrations (a biomarker of oxidation) and increase the resistance of LDL to 
oxidation in humans. Among the various beneficial effects attributed to their antioxidative 
properties, dietary soy IFs have been described as neuroprotective in transient focal cerebral 
ischemia in male and ovariectomized female rats. Consequently, IFs may protect the brain 
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via increases in endogenous antioxidant mechanisms and reduced oxidative stress (Ma et 
al., 2010).  
With regard to properties such as “protection of DNA, proteins and lipids from oxidative 
damage”, claimed as antioxidant health, the target population was assumed to be 
individuals performing physical exercise. In the context of the proposed wording, the EFSA 
Panel assumed that the claimed effect refers to the protection of DNA, proteins and lipids 
from oxidative damage caused by free radicals that are generated during physical exercise. 
However, no conclusions could be drawn from the two human studies provided for the 
scientific substantiation of the claimed effect because they do not distinguish between the 
effects of soy protein (which is the subject of the health claim) and those of soy IFs on lipid 
peroxidation. On the basis of the data presented, a cause and effect relationship was not 
established between the consumption of soy protein and the protection of DNA, proteins 
and lipids from oxidative damage (Scientific Opinion on the substantiation of health claims 
related to soy protein and contribution to the maintenance or achievement of a normal body 
weight (ID 598), maintenance of normal blood cholesterol concentrations (ID 556) and 
protection of DNA, proteins and lipids from oxidative damage (ID 435) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006, published: 19 October 2010). 
3.4 Cancer 
It has been suggested that a high intake of soy products in Asian populations may have 
contributed to cancer protection, mainly by lowering the risk at certain locations such as 
colorectal and breast cancer. The cancer protective effects of flavonoids have been attributed 
to a wide variety of mechanisms, including free radical scavenging, the modification of 
enzymes that activate or detoxify carcinogens, and inhibition of the induction of the 
transcription factor activator protein-1 (AP-1) activity by tumor promoters (Shih et al., 2000). 
Soy constituents have also been shown to have other anticancer effects, including the 
inhibition of DNA topoisomerases I and II, proteases, tyrosine kinases, inositol phosphate, 
and angiogenesis, as well as the boost of immune response and antioxidative effects 
(Adlercreutz & Mazur, 1997; Taylor et al., 2009).  
Genistein is an effective inhibitor of DMBA-induced DNA damage in MCF-7 cells by 
inhibiting CYP1A1 and CYP1B1. In fact, it inhibits recombinant human CYP1A1 and 
CYP1B1 (Chan & Leung, 2003). IFs could reduce xenobiotic-induced CYP1A1 and 1B1 
mRNA expression through interference with xenobiotic responsive elements (XRE)-
dependent transactivation (Moon et al., 2006). XRE are enhancer elements located in the 
promoter regions of xenobiotic responsive genes, which include genes encoding for CYP1A1 
and 1B1, and their expression can be regulated through pathway involving aryl 
hydrocarbon receptor (AhR). However, Kishida et al. (2004) reported that dietary soy IFs 
had no effect on the hepatic mRNA abundance of CYP1A1 and 1A2 in rats, determined by 
real-time quantitative RTPCR. This indicates that dietary IFs may not be able to induce CYPs 
in either the transcriptional step or through post-transcriptional mRNA stabilization.  
Genistein also exerts anticancer properties by modulating genes that regulate the cell cycle 
and apoptosis (Sarkar et al., 2002; Banerjee et al., 2008). As an antioxidant, genistein 
decreases reactive oxygen species levels, and it also induces the expression of the 
antioxidant enzymes superoxide dismutase (SOD) and catalase, which are associated with 
AMP-activated protein kinase (AMPK) and phosphatase and tensin homolog deleted from 
chromosome 10 (PTEN) pathways (Park et al., 2010). Genistein has been proposed as a 
natural alternative to estrogen replacement due to its ability to act via estrogen receptor-
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dependent mechanisms, utilizing the phosphatidylinositol 3-kinase /Akt pathway (Tissier 
et al., 2007). The PTEN protein is a lipid phosphatase and has been suggested to act as a 
tumor suppressor owing to its inhibition of the PI3K/Akt signalling pathway, and genistein 
has been reported to promote apoptosis in mammary epithelial cells by inducing PTEN 
(Dave et al., 2005), accompanied by a decrease in mammary tumorigenesis. 
3.4.1 Colorectal cancer 
Evidence from in vitro and animal studies has implicated soy and soy IFs in colorectal cancer 
protection. Moreover, a series of in vivo studies performed in laboratory animals have 
shown that soy diets inhibit chemically induced colon tumorigenesis, and IFs may be the 
putative bioactives playing a role in this inhibitory process (Raju et al., 2009). However, care 
should be taken when the results of these studies are analyzed, since interactions between 
soy protein and IFs may occur as well as different effects from purified extracts of IFs and 
other components such as saponins, in their anticancer effects. Soy saponins may be 
important anticancer compounds present in soy due to their ability to inhibit tumor cell 
growth without altering normal colon morphology (MacDonald et al., 2005). 
The human studies reported present a series of methodological limitations, particularly with 
regard to dietary measurement issues, such as incomplete assessment of soy intake, 
inadequate quantification, and inappropriate time period for cancer prevention as well as 
inadequate adjustment for confounders (Spector et al., 2003). Yang et al. (2009) in a 
population-based, prospective cohort of Chinese women with high but varied soy intake 
found that the risk of colorectal cancer decreased with increasing soy food intake, mainly in 
postmenopausal women. The authors reported that the risk was 30% lower among women 
in the upper third of soy food intake level compared with women in the bottom third of soy 
food intake level.  
More recently, Yan et al. (2010) developed a meta-analysis of 11 epidemiologic studies that 
assessed the association of soy consumption with colorectal cancer incidence in humans. In 
two of these studies soy intake was found to be associated with a significant reduction in 
colorectal cancer risk in women, whereas in the other nine studies no such association was 
observed in either women or men. The authors conclude that consumption of soy foods is 
not associated with the risk of colorectal cancer or colon or rectal cancer separately. 
3.4.2 Breast cancer 
An inverse relationship between soy consumption and breast cancer incidence has been 
observed in Asian populations and attributed to the high intake of soy foods. However, it is 
noteworthy that Japanese incidence rates of breast cancer have increased markedly during 
the last decades, along with Westernization of the diet and culture, while simultaneously 
breast cancer has become the number one type of cancer among Japanese women 
(http://www.mc.pref.osaka.jp/ocr/). The results of the epidemiological studies published 
are confusing, and evidence suggests that plasma or serum concentrations of IFs may be a 
more sensitive predictor of the possible protective effects of soy foods against breast cancer 
than the assessment of dietary IFs intake (Messina & Wu, 2009), mainly due to the marked 
differences in IF metabolism that exist among individuals, as well as differences in sources 
of IFs, differences in biological response to IFs among ethnic groups, interactions with 
background diet, among others. Consequently, plasma IF levels are more reliable 
biomarkers compared with dietary IFs intake for evaluating the potential of soy to reduce 
breast cancer risk.  
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One of the more intriguing subjects is that the protective effect of soy IFs observed in Asian 
studies results from lifelong exposure or exposure to IFs early in life. Although the 
preclinical models have limitations, these studies provide useful information that supports 
clinical and epidemiological studies, as is the case of the observation of a protective effect 
from early life exposure to soy IFs against breast cancer (Russo & Russo, 2006; Warri et al., 
2008; Lee et al., 2009). Undoubtedly, the most conclusive evidence of health-promoting 
effects of IFs is obtained through well designed clinical trials, and a better understanding of 
the mechanisms by which IFs may affect the development of breast cancer is still needed.  
It is noteworthy that a controversial question remains associated with the roles of IFs on 
cancer prevention. In moderation, IFs may exert beneficial effects; however, for some 
cancers, increased risk has been reported when IF intakes are high (Gee et al., 2000; Daly et 
al., 2007). In fact, Petrakis et al. (1996) demonstrated that consumption of soy protein isolate 
had stimulatory effects on the breast tissue of premenopausal women, reporting greater 
numbers of hyperplastic epithelial cells, while Allred et al. (2001) reported that soy protein 
isolates stimulated the growth of MCF-7 tumors in a dose-dependent manner as the 
concentration of genistein increased. Consequently, the IFs have paradoxical effects that 
should be taken into consideration when dosage and timing of administration are defined. 
For example, prepubertal exposure to genistein appears to be protective against the 
development of breast cancer, but consumption of the IFs in either pure form or in soy 
protein isolate, after development of an estrogen-dependent breast cancer may enhance the 
growth of that tumor (Allred et al., 2001). Shu et al. (2009) in a population based study of 
breast cancer survival demonstrated that soy food intake was associated with improved 
breast cancer survival. The authors showed that women who had the highest level of soy 
food intake and did not take tamoxifen had a lower risk of mortality and a lower recurrence 
rate than women who had the lowest level of soy food intake and used tamoxifen, 
suggesting that high soy food intake and tamoxifen use may have a comparable effect on 
breast cancer outcomes. 
4. Patents 
Patents related to soy and/or IFs may be classified into two main groups: a) those dealing 
with processes developed to obtain extracts and other forms as ingredients suitable to the 
formulation of functional foods, dietary supplements and/or nutraceuticals, and b) those 
dealing with the health-promoting effects of innovative products. Among the first group, a 
series of diverse processes have been developed, and just a few are mentioned in order to 
exemplify the diversity of subjects covered. The patented processes include, among a wide 
variety, an encapsulated soy extract that includes IF derivatives: daidzin, glycitin, genistin, 
daidzein, glycitein and genistein, encapsulated with cyclodextrins or combinations of 
various oligosaccharides (PCT/US2007/083323); a process to produce a composition 
containing a high concentration of aglycone IFs using microorganisms which are generally 
recognized as safe (GRAS), that can express or produce -glycosidase on a soy-based 
substrate (Serial No. 358938, Taiwan); a soy protein isolate that has increased amounts of IFs 
and saponins and a high Nitrogen Solubility Index ("NSI") produced by a process that 
involves ultrafiltration and the avoidance of isoelectric precipitation. The soy protein isolate 
has at least about 90.0 wt % protein of total dry matter; an IF content of at least about 1.0 
mg/g IFs of total dry matter, and a NSI of at least about 75% (US Patent 7,306,821). Methods 
of producing from natural soybeans, soybean materials (i.e. tofu dregs, soy molasses) and 
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other plant sources are also described (Appl. No. 11/622,468, Hong Kong), as well as the 
recovery of conjugated IFs of residues and sub-products of food industries based on the use 
of soy and its derivatives, including foods containing IFs and from genetically modified 
Aspergillus oryzae ATCC 22786 (RIB 430), involving a process of conversion of conjugated IFs 
(malonate and acetates), in glucosylated IFs, which through fermentative and enzymatic 
processes are transformed into aglycones (US Patent Application 20100048689). 
A series of companies have developed various soy-based products marketed to the 
treatment of various diseases and exhibit expanded patent portfolios, that include uses such 
as US patent 6,399,072 for the "Method of Preparing and Using Isoflavones for the Treatment 
of Alcoholism" and US patent 6,391,310 describing the "Method of Preparing and Using 
Isoflavones for the Treatment of Neurological Symptoms". One of the developed products 
claims a series of benefits that are a direct result of their patented, natural concentration 
process (US Patent 6,482,448 "Soy formulas and their use for promoting health"). Products 
presented as protein shakes or protein bars provide about the same amount of soy IFs found 
in 6 cups of a typical soymilk (~160 mg of soy). In the US, these products as well as others 
available should be labeled “These statements have not been evaluated by the Food and Drug 
Administration. (Name of brand) ® foods and dietary supplements are not intended to diagnose, 
treat, cure or prevent any disease. Individual results vary.”  
A series of patents describing the applications of IFs in the prevention of diseases have been 
published, mainly in the late 1990’s and early 2000’s, including situations such as cancer 
(Thurn & Juang, 1999), heart disease (Potter et al., 1999), macular degeneration (Jenks, 1999), 
as well as to prevent hair loss and maintain hair integrity (Segelman, 2000), to improve 
deficient skin conditions (Lanzendorfer et al., 1999), to inhibit Alzheimer’s disease and 
related dementias, for preserving cognitive function (Clarkson et al., 1999), to inhibit gram-
negative bacterial cytotoxicity (Fleiszig & Evans, 1999), and to treat cystic fibrosis (Hwang et 
al., 1999), among others.  
Many patents deal with the relief of menopausal symptoms, as is the case of preparations 
such as a composition claimed for the relief and/or prevention of climacteric and 
menopausal disorders affecting women in pre-, peri- or post-menopause, comprising soy IFs 
and viable lactic acid bacteria aimed to enhance the absorption of soy IFs (US Patent 
7,025,998). In this case, as in most of the patents available, the compositions are provided in 
dosage forms for oral administration (which constitute actual nutraceutical products, since 
they are presented as pharmaceutical dosage forms and are not consumed as part of the 
normal diet, a requisite for a functional food), and some commercial preparations announce 
pharmacological effects. This is the case of a soy formulation claimed to “promote the health 
of an individual, preferably utilizing the soy formulations, dietary supplements, food 
products and/or pharmacological compositions of the invention” (US Patent Application 
20030021859). A list of US patents related to soy and soy IF can be seen at http:// 
patft.uspto.gov/while in Europe the list is available at http://www.epo.org/patents 
/patent-information.html, a website that also allows to search Asian patents at 
http://www.epo.org/patents/patent-information/east-asian.html. The Google website 
http://www.google.com/patents may also be visited.  
Additionally, due to all the available information about soy IFs that in many cases may be 
confusing to the consumer, the NIH’s Office of Dietary Supplements published the fact sheet 
available at:   
http://ods.od.nih.gov/Health_Information/Information_About_Individual_Dietary_Suppl
ements.aspx 
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5. Functional foods containing soy IFs 
A series of soy based functional foods are currently marketed in many countries, most of 
which attribute beneficial effects to their IFs content. The so-called functional soy foods 
include a variety of products e.g. those traditionally fermented such as miso, tempeh, natto, 
tofu. It should be noted that fermentation of soybeans changes the amount of IFs in them. 
Amounts of IFs in the fermented soybean products miso (bean paste) and natto (fermented 
soybeans) are significantly different than those in unfermented soybeans (Fukutake et al., 
1996). The amount of genistein in the fermented soybean products is higher than in 
soybeans and soybean products such as soymilk and tofu. There is a wide variety of IF 
composition in the different soybean products commercially available as a source of 
bioactive IFs (Nurmi et al., 2002).  
Setchell et al. (2001) analyzed 33 phytoestrogen supplements and extracts available at that 
time and observed differences in the content from that claimed by the manufacturers. Novel 
fermented products include those fermented by probiotics that have the potential to reduce 
the levels of some carbohydrates responsible for gas production in the intestinal system and 
to change the bacterial composition towards a healthy population (Champagne et al., 2009). 
The most traditional concentrated and purified soy IFs are produced mostly from soy 
molasses, soy germ, and defatted soy flakes (Liu, 2004). Other soybean functional foods 
include dairy products that highlight the absence of cholesterol, lactose and milk proteins; 
bakery products; substitutes for meat, poultry or fish; and beverages (Jooyandeh, 2011).  
Boniglia et al. (2009) observed different ‘‘fingerprints” in 14 soy-based dietary supplements 
intended to help alleviate perimenopausal and menopausal symptoms on sale in Italy, 
probably on account of different sources of the soy raw materials and the methods of 
processing and preparation of extracts. These authors reported total IF levels ranging from 
33.75 to 80.00 of the values given by the manufacturers, while Stürtz et al. (2008) quantified 
the intact IFs (glycosides forms) in different supplements and observed values higher than 
those declared on the labels. These and other studies show that the IF contents are extremely 
variable and many times far below the values (34–150 mg) that appear to have some 
beneficial effects. For this reason it is important to standardize the amount of IFs present in 
these products. To overcome these inconsistencies, after analyzing a series of commercial 
products, Collison (2008) recommended an analytical method to be adopted as Official First 
Action for analysis of total soy IFs in dietary supplements, dietary supplement ingredients, 
and processed soy foods containing at least 0.5 mg/g total IFs. 
One important question that should be addressed when selecting a functional food is the 
variety and amount of bioactive ingredients it contains. Functional foods containing IFs 
should be effective to provide the benefits by consuming regular amounts of the products in 
the diet. Slavin et al. (1998) in a dose-response study suggest that the IFs in soy-protein 
isolate are bioavailable at amounts as low as 9 mg/day, or about the amount found in 28.4 g 
tofu (standard serving size), while Frank et al. (1999) reported mean total IF levels ranging 
from 35 ppm (soy milk) to 7,500 ppm (dietary supplements) in a variety of 25 soy-based 
foods and dietary supplements. It is important to keep in mind that health outcomes in 
relation to soy intake may be dependent, to some extent, on the timing and duration of soy 
exposure, the hormonal status of the individual, the tissue(s) affected, and the amount 
and/or composition of the soy consumed, and adverse effects should also be reported (Song 
et al., 2007). While traditional soy foods are comprised of a unique and complex blend of 
protein, lipids, vitamins, minerals, IFs, and other bioactive compounds that may act 
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individually and/or synergistically to exert healthful physiologic effects, there are many IF 
supplements or nutraceuticals currently available that manufacturers claim contain 1000 mg 
of genistein per dosage form (usually tablets) but for which the efficacy is unknown 
(Reinwald et al., 2010). These products should not be considered as part of a regular diet, 
however in many countries they are sold as nutritional aids. 
Additionally, all functional foods should be innocuous and secure. Thus, toxicological 
studies are a requisite for functional ingredients. The NOAEL (no observed adverse effect 
level) of genistein has been established in 50 mg/kg body weight/day by McClain et al. 
(2006), who carried out hazard analyses for acute, subchronic and chronic safety of genistein 
in rats. The US Center for the Evaluation of Risks to Human Reproduction of the National 
Toxicology Program expert review panel expressed negligible concern for adverse effects in 
the general population of consuming dietary sources of genistein, concluding that under 
current exposure conditions, adults would be unlikely to consume sufficient daily levels of 
genistein to cause adverse reproductive and/or developmental effects (Rozman et al., 2006). 
Klein & King (2007) reviewed the literature on the potential genotoxicity or cellular effects of 
high doses of genistein (> 5 μM) in vitro, an amount that is not likely to be found in vivo due 
to the low uptake and bioavailability of this compound. 
6. Conclusions 
Consumers demand the food industry to produce functional foods that contribute to 
maintain health and prevent diseases, mainly those related to the aging process. However, it 
is of major importance to provide adequate information in order to protect the consumer’s 
interests by using adequate health claims that are based upon solid scientific support 
obtained by means of in vitro, in vivo and clinical studies that substantiate the bioactivity of 
the functional ingredients contained in the products.  
Many health benefits have been attributed to soy IFs. However, to date there is only one 
accepted health claim related to dietary soy intake: it refers to soy protein, and is not 
associated to the various bioactive phytochemicals that are contained in this legume, 
including IFs. As stated by Messina (2010b) in an extensive review on the evidence of the 
health-protective effects of soy intake, there is almost no credible evidence to suggest that 
traditional soy foods exert clinically relevant adverse effects in healthy individuals when 
consumed in amounts consistent with Asian intake.  
Since the actual Western dietary IFs intake is low, an increase in dietary intake of IFs 
constitutes an interesting target and an alternative is the design of functional foods. A wide 
diversity of soy ingredients have been developed as a source of IFs that may be used as 
functional food ingredients. However, the various processes used affect the IF content and 
profile. The validation of the health claims associated to the dietary intake of putative 
bioactive IFs is a crucial issue. However, a thorough understanding of their bioavailability 
from different food products is critical to achieve the desired biological efficacy of these 
compounds. Clinical studies should be performed, although they may be costly and highly 
complex due to the various factors involved. Biological effects require sufficient delivery of 
IFs from the site of administration (the gastrointestinal tract) to the sites of target organs and 
receptors. One major factor is the bioavailability of IFs, which depends upon factors such as 
solubility, partition coefficient, permeability, metabolism, excretion, target tissue uptake, 
and disposition of the bioactives. Moreover, the poor bioavailability of polyphenols makes it 
even more difficult to conduct relevant but smaller clinical trials because large exposure 
differences are expected among the participants. 
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In spite of a myriad of patented processes and products containing soy IFs, including 
functional foods currently available for health-conscious consumers, most of the metabolic 
mechanisms of the specific health benefits attributed to IF consumption have not been 
clearly established and require further research. Consequently, no health claims should be 
declared for functional foods containing IFs, since they still lack scientific sound evidence. 
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